Black History Month 2025: Dr. Charles F. Whitten
Our first #SCDHistoryHighlight for Black History Month brings attention to the life and work of SCDAA co-founder Dr. Charles F. Whitten. Dr.... Continue Reading
SCDAA Statement on Recent Natural Disasters
SCDAA stands in solidarity with the warriors, advocates and community-based organizations who have been recently affected by natural disasters, including the... Continue Reading
SCDAA names board officers
The Sickle Cell Disease Association of America Inc., a national nonprofit membership organization that advocates for people affected by sickle cell... Continue Reading
MARAC Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal
SCDAA Medical and Research Advisory Committee (MARAC) Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal 9/27/24 What is the news? Pfizer announced the withdrawal... Continue Reading
Sickle Cell Disease is Not a Joke
This weekend’s Saturday Night Live skit about the recent historic approvals of potentially curative gene therapies for sickle cell disease is... Continue Reading
SCDAA Statement About Gene Therapy Approval
On Dec. 8, 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for sickle cell disease (SCD), Casgevy... Continue Reading
Gene Therapy is Approved!
We are very excited to share that today, Dec. 8, the Food and Drug Administration approved two gene therapies to treat... Continue Reading
Sickle Cell Awareness Month 2023 Events
All across the country, our member organizations are hosting exciting events for Sickle Cell Awareness Month this September. Check out the... Continue Reading
SCDAA Teams with MedicAlert Foundation
Sickle Cell Disease Association of America Teams with MedicAlert Foundation to Improve Emergency Outcomes During Sickle Cell Crises Nonprofits partner to... Continue Reading
Afimmune joins the SCD C.A.R.E.S. Consortium
Dublin, Ireland, 19 June 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced it has been invited to... Continue Reading